iCoat Medical, headquartered in Stockholm and with operations in Uppsala and Lund, is a pharmaceutical company conducting clinical research to reduce ischemia-reperfusion injuries with a primary focus on kidney transplantation. iCoat Medical’s clinical drug candidate iCM012, based on 25 years of research and development in collaboration with leading academic institutes, is developed to improve the outcome of organ transplants.
